Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 6/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31693832 | 1.00 | TACR1 (0.53) | TACR1ATMGPR119TSHRALOX15 | |
| SCHEMBL701407 | 0.89 | TACR1 (0.53) | TACR1ATMGPR119TSHRALOX15 | |
| SCHEMBL2469527 | 0.88 | TACR1 (0.52) | TACR1ATMGPR119TSHRALOX15 | |
| SCHEMBL19226428 | 0.87 | TACR1 (0.60) | TACR1ATMGPR119TSHRALOX15 | |
| SCHEMBL4407248 | 0.87 | TACR1 (0.62) | TACR1ATMTSHRALOX15OPRD1 | |
| SCHEMBL4414050 | 0.87 | CCR5 (0.53) | TACR1ATMTSHRALOX15OPRD1 | |
| SCHEMBL4159626 | 0.86 | HSD11B1 (0.56) | TACR1ATMTSHRALOX15CCR5 | |
| SCHEMBL4542548 | 0.85 | TACR1 (0.49) | TACR1ATMGPR119TSHRALOX15 | |
| SCHEMBL701270 | 0.85 | TACR1 (0.49) | TACR1ATMGPR119TSHRALOX15 | |
| SCHEMBL2470882 | 0.84 | TACR1 (0.48) | TACR1ATMGPR119TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558577-B1 | SUBSTITUTED 4-PHENYL-PIPERIDIN-AMIDES AS TACHYKININ ANTAGONISTS AND SEROTONIN REPTAKE INHIBITORS | GLAXO GROUP LTD (GB) | 2009-12-30 | — | — | EP | disclosed |
| US-20060128752-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128752-A1 | Chemical compounds | HTR7, NPSR1, TACR2 | TACR1 6/4885ATM 3525/4885GPR119 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.